Insilico Medicine Is Said to Aim for Hong Kong Listing in Coming Weeks
A technician operates at a lab in Insilico Medicine's research facility in Suzhou, China.
Photographer: Qilai Shen/BloombergInsilico Medicine Inc. aims to list in Hong Kong as soon as this month, according to people familiar with the matter, rounding out a more than four-year effort to go public.
The company, a drug discovery and development platform supported by generative artificial intelligence, intends to raise about $300 million, the people said, asking not to be identified because the information is private.